Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)

DRUG2 trials

Sponsors

Fox Chase Cancer Center, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Conditions

Non-Small Cell Lung CancerPancreatic Adenocarcinoma

Phase 1

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

RecruitingNCT06892054

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Pancreatic Adenocarcinoma

Start: 2025-08-08End: 2030-08-08Target: 15Updated: 2026-04-30

Phase 2

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

WithdrawnNCT05400577

Fox Chase Cancer CenterNon-Small Cell Lung Cancer

Start: 2022-07-13End: 2024-02-01Updated: 2023-07-17